Projected lives saved and economic value of mRNA cancer immunotherapies in the United States.
mRNA cancer vaccines could prevent nearly 50,000 US deaths yearly across multiple cancer types if widely adopted, representing substantial health and economic gains.
mRNA cancer immunotherapies could avert ~49,415 US deaths/year (95% CrI: 28,233-71,085) among NSCLC, pancreatic, renal cell carcinoma, and melanoma patients, with an estimated economic value of $75.55 billion—far exceeding current US funding cuts to the mRNA platform. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- mathematical_modeling
- Category
- novel_therapeutics
- Maturity
- Validated
- Journal
- Lancet Regional Health Americas
Why it surfaced
Lancet journal; Yale Center for Infectious Disease Modeling; highly timely public health policy analysis in context of US mRNA research funding cuts; relevant to T6 immunotherapy watchlist and broader mRNA oncology platform development.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.